FCR achieves long-term durable remissions in patients with IGHV-mutated CLL.

Related Articles

FCR achieves long-term durable remissions in patients with IGHV-mutated CLL.

Blood. 2017 Nov 23;130(21):2278-2282

Authors: Chai-Adisaksopha C, Brown JR

Abstract
In chronic lymphocytic leukemia (CLL) patients with mutated IGHV, 3 recent studies have demonstrated prolonged progression-free survival (PFS) after treatment with fludarabine-cyclophosphamide-rituximab (FCR) chemoimmunotherapy. We performed a systematic review to assess the benefit of FCR for patients with CLL and identified 5 randomized trials that met our inclusion criteria. FCR improved complete remission, PFS and overall survival vs the comparator; median PFS was not reached in the subgroup of CLL patients with mutated IGHV.

PMID: 29025740 [PubMed - indexed for MEDLINE]

http://ift.tt/2AA45Gu